Adding Chemotherapy in Medulloblastoma Linked With Improved Survival

Video

A recent retrospective study found that adding chemotherapy to postoperative treatment of craniospinal radiation for adults with medulloblastoma improves survival.

A recent retrospective study found that adding chemotherapy to postoperative treatment of craniospinal radiation improves survival in adult medulloblastoma patients.

The study examined 751 patients from the National Cancer Data Base: 520 received both chemotherapy and radiation therapy following surgery, and 231 received only radiation therapy. Estimated overall survival at 5 years was 86.1% in patients who received chemotherapy compared with 71.6% in patients who received radiation alone. One of the study limitations was the lack of information on tumor mutation status.

In this video Benjamin Kann, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses the results.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.